Showing results (121-130 of 149) with videos related to

Sort By:
Pageof 15
Cancer Cell|May 5, 2023
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyMark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, et al.
Breast Cancer Research and Treatment|May 8, 2020
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015Peter H O'Donnell, Vassily Trubetskoy, Ashley Nurhussein-Patterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2021
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast CancerBryan P Schneider, Guanglong Jiang, Tarah J Ballinger, et al.
JAMA Oncology|July 10, 2020
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical TrialMilan Radovich, Guanglong Jiang, Bradley A Hancock, et al.
Medrxiv : the Preprint Server for Health Sciences|September 5, 2025
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast CancerFrederick M Howard, James Dolezal, Hanna Hieromnimon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2026
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual DiseaseNatasha B Hunter, Heather A Parsons, Leslie Cope, et al.
NPJ Breast Cancer|August 23, 2018
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response EndpointJudy C Boughey, Michael D Alvarado, Rachael B Lancaster, et al.
JAMA Network Open|December 28, 2023
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast CancerBeverly Kyalwazi, Christina Yau, Michael J Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.
Pageof 15